A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis.
By C. Polman, P. W. O'connor, E. Havrdová, M. Hutchinson, L. Kappos, David H. Miller, J. Phillips, F. Lublin, G. Giovannoni, A. Wajgt and 4 more. New England Journal of Medicine, 2006
3,224 citations recorded by the source corpus.
Subfields: Immunology, Immunology and Allergy, Pathology and Forensic Medicine
View Paper: https://www.semanticscholar.org/paper/c180dc4a069a4c609ed32d6317ead7efb0d667ff
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Immunology
In Pathology and Forensic Medicine
Citations in the corpus
- Network-based prediction of drug combinations (2019, background): “However, the targets of natalizumab (N), an FDA-approved monoclonal antibody for treating multiple sclerosis 24 , are in a topologically distinct neighborhood from the targets of imatinib and tandutinib, having a positive s IN = 0.59 and s TN = 0.49, respectively (Fig.”
- Multiple sclerosis: a complicated picture of autoimmunity (2007, background): “Natalizumab produces a very rapid decrease in contrast-enhancing MRI lesions as well as a reduction in clinical relapse”
- Experimental autoimmune encephalomyelitis (EAE) as a model for multiple sclerosis (MS) (2011, background): “The drug was cautiously re-introduced in 2006 after safety review, under a special prescription and observation programme, as the clinical benefits in people with aggressive RRMS are judged to outweigh the risks (Polman et al., 2006; Goodin et al., 2008).”
- Mechanism of Action of Oral Fingolimod (FTY720) in Multiple Sclerosis (2010, result): “Another DMT, natalizumab, seems to be more effective than current first-line DMTs, as suggested by results of a phase 3 study that demonstrated a reduction in relapse rate of approximately 65% compared with that with placebo and a reduction in risk of sustained disability progression over 2 years of”